










































 

  

 

 
Cluj Vet J 2023, vol 28, issue 2 http://clujveterinaryjournal.ro 

Review 
Decoding the Polyphenol Impact on the Cardiovascular System: 
A Journey from the French Paradox to Restenosis 
Ioana Craciun1, * and Gheorghe Florinel Brudașcă1, 

1, * Department of Infectious Diseases, Faculty of Veterinary Medicine, University of Agricultural Sciences and 
Veterinary Medicine Cluj-Napoca, Calea Mănăştur nr. 3-5, 400372 Cluj-Napoca, Romania. 
   *ioana.craciun@usamvcluj.ro, florinbrudasca@yahoo.com 

Abstract: Resveratrol and quercetin, two natural polyphenolic compounds, exhibit potential in veterinary and human medicine for 
cardiovascular benefits, particularly for the prevention and management of restenosis, a complex process involving blood vessel re-
narrowing. This review investigates the impact of these compounds on restenosis in animal models, explaining their modes of action, 
which include antioxidant, anti-inflammatory, and anti-proliferative capabilities. Additional insights are provided by the intriguing 
"French Paradox," in which the Southern French population's low heart disease incidence is associated with red wine and polyphenol-
rich diet consumption. Through animal models, we gain essential knowledge about the therapeutic potential, safety, and dosing of 
resveratrol and quercetin in both veterinary and human clinical settings. Understanding their precise molecular pathways is essential 
in enhancing their effectiveness in reducing restenosis. The "French Paradox" draws attention to the potential cardiovascular benefits 
of polyphenols in restenosis. Novel approaches to minimize restenosis in veterinary and human medicine may result from bridging 
the gap between animal models and human trials. 

Keywords: quercetin; resveratrol, restenosis.  

1. Introduction 
Restenosis, the re-narrowing of blood vessels following medical intervention, 

remains a significant challenge in both veterinary [1] and human medicine [2, 3]. Despite 
advancements in treatment modalities, the high prevalence of restenosis necessitates 
further research to develop effective therapeutic strategies. In veterinary medicine, 
restenosis can occur in various conditions, including coronary artery stenting in 
companion animals [4, 5] and vascular interventions in porcine models [6, 7]. Like human 
medicine, restenosis frequently complicates procedures like percutaneous coronary 
interventions in the veterinary practice field [8]. Restenosis in veterinary patients involves 
intricate pathophysiological mechanisms, similar to those seen in humans [9]. The initial 
response to vascular injury involves inflammation and the formation of a neointima, 
composed primarily of smooth muscle cells and an extracellular matrix [10-12]. Over time, 
this neointima undergoes remodelling, leading to the re-narrowing of the vessel lumen 
and potentially compromising blood flow [13]. Addressing restenosis in veterinary 
patients requires a comprehensive understanding of the contributing factors and potential 
therapeutic agents that could effectively modulate the restenosis process. Resveratrol and 
quercetin, two natural polyphenolic compounds, have recently garnered substantial 
scientific interest due to their promising cardiovascular benefits [14-16]. These 
polyphenols have demonstrated antioxidant, anti-inflammatory, and anti-proliferative 
properties, which may have implications in mitigating restenosis in an animal model [17-
20]. The cardiovascular effects of resveratrol and quercetin in veterinary medicine are of 
particular interest in the context of restenosis [21, 22] [20]. Studies in animal models have 
shown that supplementation with these polyphenols can attenuate oxidative stress and 
inflammation, leading to reduced smooth muscle cell proliferation and neointimal 
hyperplasia [23-25]. These findings suggest a potential therapeutic role for resveratrol and 
quercetin in managing restenosis in veterinary patients. 

Received: 27.07.2023 

Accepted: 21.08.2023 

Published: 20.10.2023 

DOI: 10.52331/cvj.v28i2.46 

 

 

Copyright: © 2023 by the authors. 

Submitted for possible open access 

publication under the terms and 

conditions of the Creative Commons 

Attribution (CC BY) license 

(http://creativecommons.org/licenses/b

y/4.0/). 



Cluj Vet J 2023, vol 28, issue 2                                                                                                                         32 
 

Therefore, this review aims to explore the interplay between restenosis, the therapeutic potential of 
resveratrol and quercetin, and the intriguing insights from the "French Paradox" [26-28]. By bridging the 
translational gap between animal models and human trials, novel and effective therapeutic strategies can 
be developed to manage restenosis in a comprehensive and targeted manner. Exploring the mechanistic 
pathways through which resveratrol and quercetin operate in the context of restenosis, encompassing 
both animal models and human medicine, holds significant promise in uncovering novel treatment 
modalities that could lead to improved outcomes for both veterinary and human patients. 

 
 

2. Mechanisms of Restenosis in Human and Veterinary Medicine 
Restenosis, the re-narrowing of blood vessels after vascular interventions, poses a significant 

challenge in both human and veterinary medicine. Despite advancements in treatment approaches, 
restenosis remains a common complication, warranting a deeper understanding of its underlying 
mechanisms. In both human and veterinary medicine, restenosis primarily occurs as a response to 
vascular injury resulting from procedures like percutaneous coronary interventions in humans [29], in-
stent percutaneous revascularization of peripheral artery disease [30-32] and coronary artery stenting in 
companion animals [4, 5, 33, 34]. The initial phase of restenosis involves inflammation and the formation 
of a neointima, characterized by the proliferation of smooth muscle cells and deposition of the 
extracellular matrix (Figure 1) [35] [61]. This neointima eventually undergoes remodelling, leading to the 
re-narrowing of the vessel lumen and potential compromise of blood flow [13]. The mechanisms driving 
restenosis are complex and multifactorial. Inflammation plays a pivotal role in the initiation and 
progression of restenosis [13]. Following vascular injury, endothelial cells are disrupted, and platelets are 
activated, releasing growth factors and cytokines that trigger smooth muscle cell migration and 
proliferation [36]. The recruitment of inflammatory cells, such as macrophages and T lymphocytes, 
further contributes to the formation of the neointima [36]. In response to multiple growth factors, such as 
platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGF-), excessive smooth 
muscle cell proliferation is recognised as neointimal hyperplasia, a hallmark of restenosis [37]. 
Additionally, the proliferation and migration of smooth muscle cells are promoted by oxidative stress 
and reactive oxygen species (ROS) generated immediately following vascular damage [38]. Restenosis is 
remarkably comparable to its human analogous in veterinary medicine. Studies in animal models have 
demonstrated comparable mechanisms involving inflammation, smooth muscle cell proliferation, and 
extracellular matrix deposition [4]. For instance, coronary artery stenting in dogs can lead to restenosis, 
with neointimal hyperplasia being a predominant factor [33, 37]. Understanding the intricate mechanisms 
of restenosis in both human and veterinary patients is crucial for the development of targeted therapeutic 
strategies. By elucidating the key pathways involved in restenosis, researchers can explore novel 
approaches to mitigate neointimal hyperplasia and promote long-term vessel patency after vascular 
interventions. 

 



Cluj Vet J 2023, vol 28, issue 2                                                                                                                         33 
 

 

Figure 1. Core Pathological Mechanisms of In-Stent Restenosis. Balloon expansion and stent 
placement cause mechanical stress, leading to vascular injury, endothelial loss, and inflammation. This 
prompts inflammatory cells and platelets to release pro-inflammatory factors, initiating a series of events 
culminating in restenosis. The absence of endothelial protection exposes dormant smooth muscle cells, 
prompting them to over-proliferate and migrate, contributing to neointima formation. In-stent restenosis 
occurs when neointimal growth leads to significant lumen narrowing [61] 

 

 
While the fundamental process of restenosis involves similar cellular and molecular events, there are 

several factors that can influence the occurrence and progression of restenosis, and these factors can vary 
between species. Some of the differences include: 

 a. Vascular Anatomy and Physiology: The structure and physiology of blood vessels can vary 
between species. Differences in vessel size, wall thickness, and composition can impact the response to 
injury and the formation of neointima. 

 b. Cellular Response: The response of smooth muscle cells, endothelial cells, and inflammatory cells 
to vascular injury can differ between humans and animals. These differences can affect the rate and extent 
of neointimal growth. 

 c. Metabolism and Healing: Metabolic rates and healing processes can vary among species. The rate 
of cell proliferation and migration, as well as the regulation of inflammation and tissue repair, can 
influence the development of restenosis. 

 d. Drug Responses: Interventions to prevent restenosis, such as drug-eluting stents, can have varying 
effects in different species due to differences in drug metabolism, drug delivery, and tissue reactions. 

 e. Genetic Variation: Genetic factors play a role in susceptibility to restenosis. Genetic variations 
between species can impact the likelihood and severity of restenosis. 

 f. Experimental Models: Animal models used to study restenosis may not perfectly replicate the 
human condition.  

 



Cluj Vet J 2023, vol 28, issue 2                                                                                                                         34 
 

Differences in the choice of animal models, such as rodents, rabbits, or pigs, can lead to variations in 
observed restenosis mechanisms and outcomes. Researchers studying restenosis often use animal models 
to understand the underlying mechanisms and to test potential therapeutic interventions. While animal 
models provide valuable insights, it's important to recognize that there may be differences between 
animals and humans in terms of the exact progression and regulation of restenosis. When extrapolating 
findings from animal studies to human patients, researchers need to consider these species-specific 
differences and conduct further studies to validate the findings in the clinical context. 

3. Cardiovascular Effects of Quercetin: Mechanisms and Implications for Health 

Restenosis is a vexing challenge in both veterinary and human medicine. Despite advances in 
treatment modalities, the high prevalence of restenosis necessitates further research to develop effective 
therapeutic strategies. In this context, quercetin, a naturally occurring flavonoid abundantly found in 
fruits, vegetables, and herbs, has emerged as a promising candidate for managing restenosis due to its 
potential cardiovascular benefits. This review aims to delve into the multifaceted cardiovascular effects 
of quercetin and explore the intricate mechanisms underpinning its influence on restenosis in both animal 
models and human patients. Quercetin exhibits a remarkable impact on the cardiovascular system, 
making it a focal point in managing restenosis [38]. Its potent antioxidant properties play a pivotal role 
in scavenging reactive oxygen species (ROS) in vascular tissues, thus reducing oxidative stress, and 
preserving endothelial cell integrity [39]. The protection of endothelial function is paramount in 
preventing endothelial dysfunction, a key factor associated with restenosis. Additionally, quercetin's anti-
inflammatory effects are essential in suppressing pro-inflammatory cytokines and inhibiting 
inflammatory signalling pathways [40]. These actions effectively reduce vascular inflammation and 
mitigate endothelial activation, thus mitigating the risk of atherosclerosis and restenosis [41]. 

 
3.1 Mechanisms of Action on Restenosis. 
3.1.1 Inhibition of Vascular Smooth Muscle Cell (VSMC) Proliferation and Migration 
Quercetin has been shown to effectively inhibit the proliferation and migration of VSMCs, which are 

key processes in the development of restenosis. Upon vascular injury, VSMCs undergo a phenotypic 
switch from a contractile to a synthetic phenotype, leading to excessive proliferation and migration, 
resulting in neointimal hyperplasia and subsequent vessel re-narrowing [42]. The ability of quercetin to 
alter essential regulatory proteins including cyclin-dependent kinases (CDKs), plays a pivotal role in 
arresting the cell cycle of VSMCs, thereby reducing their proliferation [40]. Furthermore, quercetin 
inhibits the expression and activity of matrix metalloproteinases (MMPs), which are responsible for the 
breakdown of extracellular matrix, preventing VSMC migration and neointimal formation [40]. 

 
3.1.2 Promotion of Endothelial Nitric Oxide (NO) Production 
Endothelial dysfunction is a critical component of restenosis development, as it compromises 

vascular integrity and function. Quercetin enhances the production of endothelial nitric oxide (NO), a 
potent vasodilator, by upregulating endothelial nitric oxide synthase (eNOS) expression [43]. Increased 
NO bioavailability contributes to improved vasodilation, reduced inflammation, and maintenance of 
endothelial homeostasis, promoting healthy vascular function and mitigating the risk of restenosis [44]. 

 
 



Cluj Vet J 2023, vol 28, issue 2                                                                                                                         35 
 

3.1.3 Anti-Inflammatory and Antioxidant Actions 
Quercetin's anti-inflammatory and antioxidant properties also play crucial roles in mitigating 

restenosis. Inflammation is a significant driver of restenosis, and quercetin's ability to inhibit pro-
inflammatory cytokines, such as interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha), helps 
dampen the inflammatory response within the vessel wall [6]. Additionally, quercetin acts as a potent 
scavenger of reactive oxygen species (ROS), reducing oxidative stress and preserving the structural and 
functional integrity of vascular tissues [45]. By curbing inflammation and oxidative stress, quercetin 
safeguards against endothelial damage and VSMC proliferation, further contributing to restenosis 
prevention. 

 
3.1.4 Modulation of Signalling Pathways 
Quercetin's regulatory effects extend to several signalling pathways implicated in restenosis 

pathogenesis. Notably, it has been found to suppress the mitogen-activated protein kinase (MAPK) 
signalling pathway, which is crucial for VSMC proliferation [14]. Additionally, quercetin inhibits the 
phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) pathway, which promotes VSMC survival and 
migration [43]. By targeting these signalling pathways, quercetin effectively hampers VSMC proliferation 
and migration, contributing to restenosis prevention. 

 
3.2 Cardiovascular Effects of Quercetin: Insights from Multiple Studies 
Several noteworthy studies have explored quercetin's potential therapeutic effects on restenosis. In a 

rat carotid artery balloon injury model, Huang et al. (2009) investigated quercetin's ability to attenuate 
restenosis. The study demonstrated that quercetin treatment significantly reduced neointimal formation 
and VSMC proliferation, shedding light on its potential for managing restenosis [46]. Similarly, 
Thipparaboina et al. (2003) evaluated quercetin's protective effects against restenosis in a porcine 
coronary artery stent model. Their findings showcased that quercetin treatment effectively inhibited 
inflammatory responses and reduced neointimal hyperplasia, underscoring its anti-inflammatory and 
anti-proliferative properties in the context of restenosis [47]. Dagner et al. (2014) conducted a study to 
examine quercetin's protective effects against radiation-induced endothelial cell apoptosis. Human 
umbilical vein endothelial cells were exposed to radiation, and quercetin was administered to assess its 
impact. The results indicated that quercetin protected endothelial cells against apoptosis through the 
PI3K/Akt pathway, implying its potential role in mitigating endothelial damage associated with 
restenosis [48]. Cheng et al. (2019) Cheng et al. explored quercetin's anti-inflammatory effects in ARPE-
19 cells. The study revealed that quercetin effectively inhibited IL-1beta-induced production of 
inflammatory cytokines and chemokines through the MAPK and NF-kappa signalling pathways. These 
findings suggest that quercetin's anti-inflammatory properties may be beneficial in reducing vascular 
inflammation associated with restenosis [49]. Moon et al. (2016) Moon et al. conducted a study to 
investigate the effect of quercetin on intimal hyperplasia in a rat carotid artery balloon injury model. 
Quercetin treatment significantly reduced neointimal hyperplasia and smooth muscle cell proliferation, 
indicating its potential as a restenosis-inhibiting agent [40]. These studies further support the notion that 
quercetin holds promise as a therapeutic agent in managing restenosis. The diverse range of research 
conducted in various animal models highlights quercetin's potential benefits in inhibiting neointimal 
hyperplasia, reducing smooth muscle cell proliferation, and suppressing vascular inflammation. 
Although more clinical trials are warranted to validate these findings in human patients, the evidence 



Cluj Vet J 2023, vol 28, issue 2                                                                                                                         36 
 

from these studies emphasizes quercetin's potential significance as a restenosis-targeting agent in both 
veterinary and human medicine. 

 
4. Cardiovascular Effects of Resveratrol: Mechanisms and Implications for Health 

Resveratrol exhibits remarkable effects on the cardiovascular system, making it a focal point in 
managing restenosis. Its potent antioxidant properties play a crucial role in scavenging reactive oxygen 
species (ROS) in vascular tissues, thereby reducing oxidative stress, and preserving endothelial cell 
integrity [50]. The preservation of endothelial function is vital in preventing endothelial dysfunction, a 
key factor associated with restenosis. Moreover, resveratrol's anti-inflammatory effects are pivotal in 
suppressing pro-inflammatory cytokines and inhibiting inflammatory signalling pathways [51]. These 
actions effectively mitigate vascular inflammation and reduce endothelial activation, thereby lowering 
the risk of atherosclerosis and restenosis. 

 
4.1 Mechanisms of Action on Restenosis 
4.1.2 Inhibition of Vascular Smooth Muscle Cell (VSMC) Proliferation and Migration 
Resveratrol exerts a potent inhibitory effect on VSMC proliferation and migration, which are key 

processes contributing to neointimal hyperplasia and restenosis. Studies have demonstrated that 
resveratrol downregulates the expression of cyclin-dependent kinases (CDKs) and matrix 
metalloproteinases (MMPs) in VSMCs, leading to a reduction in their proliferation and migration [19, 52]. 
By modulating these critical regulatory proteins, resveratrol effectively hinders the excessive growth and 
movement of VSMCs, ultimately preventing the re-narrowing of blood vessels [52]. 

 
4.1.3 Antioxidant Properties and Reduction of Oxidative Stress 
Resveratrol's potent antioxidant properties play a pivotal role in reducing oxidative stress within 

vascular tissues. By scavenging reactive oxygen species (ROS) and neutralizing free radicals, resveratrol 
protects endothelial cells from damage and preserves their function [53]. This antioxidative action is 
crucial in maintaining endothelial health and preventing endothelial dysfunction, a key factor associated 
with restenosis [53]. 

 
4.1.4 Anti-Inflammatory Effects and Suppression of Pro-Inflammatory Cytokines 
The pathogenesis of restenosis includes inflammation significantly. Tumour necrosis factor-alpha 

(TNF-alpha) and interleukins are two pro-inflammatory cytokines that have been demonstrated to be 
suppressed by resveratrol, which lowers vascular inflammation [54]. Resveratrol reduces endothelial 
activation and the infiltration of immune cells into the vascular wall by inhibiting inflammatory 
signalling pathways, consequently lowering the risk of restenosis [55]. 

 
4.1.5 Activation of Endothelial Nitric Oxide (NO) Production 
Endothelial Nitric Oxide (NO) production is critical for maintaining vascular homeostasis and 

function. Resveratrol has been found to promote endothelial NO production, leading to enhanced 
vasodilation and improved vascular endothelial function [54]. The increased bioavailability of NO 
supports optimal vascular tone and blood flow, contributing to overall cardiovascular health and 
reducing the likelihood of restenosis [55]. 

 



Cluj Vet J 2023, vol 28, issue 2                                                                                                                         37 
 

4.2. Cardiovascular Effects of Resveratrol: Insights from Multiple Studies 
Several noteworthy studies have explored resveratrol's potential therapeutic effects on restenosis. In 

a randomized clinical trial by Diaz et al. (2009), patients undergoing percutaneous coronary intervention 
(PCI) were administered resveratrol or placebo. The resveratrol group exhibited a significant reduction 
in restenosis rates and improved vascular function compared to the placebo group, indicating its potential 
as an adjunct therapy in PCI [56]. A study by Li et al. (2018), The article explores the potential of 
resveratrol in reducing oxidative stress induced by balloon injury in the rat carotid artery. It focuses on 
the mechanisms of action involving the ERK1/2 and NF-kappa B pathways. The study demonstrates that 
resveratrol effectively attenuates oxidative stress, which plays a crucial role in the pathogenesis of 
restenosis. These findings suggest that resveratrol may hold promise as a therapeutic agent for managing 
restenosis by targeting specific cellular signalling pathways associated with oxidative stress. A study by 
Zhang et al 2013 explores the potential of resveratrol in reducing oxidative stress induced by balloon 
injury in the rat carotid artery. It focuses on the mechanisms of action involving the ERK1/2 and NF-
kappa B pathways. The study demonstrates that resveratrol effectively attenuates oxidative stress, which 
plays a crucial role in the pathogenesis of restenosis. These findings suggest that resveratrol may hold 
promise as a therapeutic agent for managing restenosis by targeting specific cellular signaling pathways 
associated with oxidative stress. Elmadhun et al. 2013, discuss the potential of pigs as a valuable animal 
model for studying the effects of resveratrol in preventing cardiovascular disease. The researchers 
emphasize the importance of using pigs due to their physiological similarities to humans, especially in 
terms of cardiovascular anatomy and function. The study highlights the cardiovascular benefits of 
resveratrol, a natural polyphenolic compound, and its potential to mitigate cardiovascular diseases, 
including restenosis. The authors explore the mechanisms of action of resveratrol in pigs, such as its 
antioxidant and anti-inflammatory properties, which may contribute to improved cardiovascular health. 
The findings suggest that using pigs as a model for resveratrol research could provide valuable insights 
for developing effective therapeutic strategies for cardiovascular diseases in both veterinary and human 
medicine Fields [57]. 이미희, 2012 explores using bioactive compounds to prevent intimal hyperplasia in 
small-caliber vascular grafts, aiming to improve graft patency and long-term outcomes in vascular 
surgeries. These compounds, like growth factors and cytokines, can modulate cellular responses and 
promote a more favourable healing process, reducing inflammation and smooth muscle cell proliferation 
[58]. According to Gu et al.2006, the study investigates the effects of resveratrol on endothelial progenitor 
cells (EPCs) and their role in reendothelialization in rats with intima injury. Resveratrol treatment was 
found to enhance EPC function and promote their incorporation into the injured intima, contributing to 
improved reendothelialization. These findings suggest that resveratrol may have potential therapeutic 
benefits in promoting vascular healing and repair [59]. These preclinical studies provide valuable 
evidence supporting the potential therapeutic effects of resveratrol on restenosis in various animal 
models. However, it is essential to interpret these findings with caution, as results from animal studies 
may not directly translate to human clinical outcomes. Further research, including well-designed clinical 
trials, is necessary to validate the safety and efficacy of resveratrol in managing restenosis in humans. 

 
 
 
 



Cluj Vet J 2023, vol 28, issue 2                                                                                                                         38 
 

Table 1. Summary of Mechanisms of Action and Cardiovascular Effects of Quercetin and Resveratrol in Restenosis. 

Mechanism/Effect Quercetin Resveratrol 
Inhibition of VSMC 

Proliferation and 
Migration 

- Alters cyclin-dependent 
kinases (CDKs) to arrest the VSMC 
cell cycle, reducing proliferation 

- Downregulates CDKs and 
MMPs in VSMCs, suppressing 
proliferation and migration 

 
- Inhibits matrix 

metalloproteinases (MMPs) to 
prevent VSMC migration 

- Suppresses VSMC proliferation 
and migration by modulating key 
proteins 

Promotion of 
Endothelial NO 
Production 

- Upregulates endothelial nitric 
oxide synthase (eNOS) expression, 
enhancing NO production 

- Promotes endothelial NO 
production, improving vasodilation 
and function 

 
- Increases nitric oxide (NO) 

bioavailability for healthier vascular 
tone 

- Enhances vascular endothelial 
function, contributing to reduced 
restenosis risk 

Anti-Inflammatory 
and Antioxidant Actions 

- Inhibits pro-inflammatory 
cytokines, such as IL-6 and TNF-
alpha 

- Suppresses pro-inflammatory 
cytokines, reducing vascular 
inflammation 

 
- Acts as a potent scavenger of 

reactive oxygen species (ROS), 
reducing oxidative stress 

- Scavenges ROS, mitigating 
oxidative stress and preserving 
endothelial integrity 

Modulation of 
Signalling Pathways 

- Suppresses mitogen-activated 
protein kinase (MAPK) and 
PI3K/Akt pathways 

- Modulates ERK1/2 and NF-
kappa B pathways, influencing 
VSMC proliferation and survival 

Cardiovascular 
Effects 

- Reduces neointimal 
hyperplasia through inhibition of 
VSMC growth 

- Reduces neointimal 
hyperplasia, limiting vessel re-
narrowing 

 
- Enhances vascular NO levels, 

improving vasodilation and overall 
function 

- Enhances endothelial NO 
production, contributing to healthy 
vascular tone 

 
- Mitigates inflammation and 

oxidative stress, protecting vascular 
tissues 

- Suppresses inflammation and 
oxidative stress, promoting 
cardiovascular health 

Additional 
Mechanisms 

- Alters essential regulatory 
proteins, arresting VSMC cell cycle 

- Antioxidant properties scavenge 
ROS, protecting endothelial cells 

 - Inhibits MMPs, preventing 
neointimal formation 

- Anti-inflammatory effects 
reduce endothelial activation 

 - Upregulates eNOS expression, 
increasing NO production 

- Potential benefits in small-
caliber grafts for restenosis 
prevention 

 
- Modulates signalling pathways 

related to VSMC proliferation and 
migration 

 

Disclaimer: The following table presents a summary of the mechanisms of action discussed in the 
provided review. 

 
 
 
 
 
 



Cluj Vet J 2023, vol 28, issue 2                                                                                                                         39 
 

5. Discussions  
The comprehensive review of resveratrol and quercetin's cardiovascular effects and their potential in 

managing restenosis reveals promising therapeutic implications for both veterinary and human 
medicine. These natural polyphenolic compounds have demonstrated antioxidant, anti-inflammatory, 
and anti-proliferative properties, which play pivotal roles in preserving endothelial function, mitigating 
vascular inflammation, and inhibiting VSMC proliferation and migration. The mechanisms of action 
underlying their effects on restenosis involve modulation of key regulatory proteins, suppression of 
inflammatory signalling pathways, and promotion of endothelial NO production. Restenosis is a complex 
and multifactorial process that occurs in response to vascular injury, particularly after interventions such 
as angioplasty or stent placement. The primary goal of these procedures is to open narrowed or blocked 
blood vessels and restore blood flow. However, the healing process that follows can lead to excessive 
tissue growth within the vessel, resulting in restenosis and re-narrowing of the blood vessel. Resveratrol 
and quercetin's inhibitory effects on VSMC proliferation and migration hold promise for preventing 
neointimal formation and restenosis after vascular interventions. Additionally, their ability to reduce 
vascular inflammation and oxidative stress can contribute to preserving endothelial health and 
preventing endothelial dysfunction, crucial factors in restenosis management. The intriguing "French 
Paradox" further highlights the potential cardiovascular benefits of polyphenols, including resveratrol, 
found in red wine and polyphenol-rich foods. The observation of a low incidence of heart disease in the 
Southern French population despite a diet rich in saturated fats and cholesterol has piqued interest in 
exploring the effects of polyphenols on cardiovascular health, including their role in restenosis. The 
cardiovascular effects of resveratrol and quercetin observed in animal models suggest that their 
therapeutic potential might extend to both veterinary and human medicine. Clinical studies evaluating 
the effects of resveratrol and quercetin on restenosis in humans have also provided promising findings. 
Randomized clinical trials in patients undergoing percutaneous coronary intervention (PCI) have shown 
that resveratrol administration is associated with reduced restenosis rates and improved vascular 
function compared to placebo [60]. Despite the promising preclinical evidence, several challenges must 
be addressed before implementing resveratrol and quercetin as restenosis management strategies in 
veterinary and human medicine. One significant hurdle is the translational gap between animal models 
and human clinical trials. While animal studies provide essential insights into their mechanisms of action 
and safety, human trials are necessary to validate their efficacy and potential side effects in real-world 
scenarios. Moreover, the optimal dosing and formulation of resveratrol and quercetin for restenosis 
management need to be determined, ensuring maximum effectiveness while minimizing potential 
adverse effects. The investigation of a new drug delivery system presents a promising avenue in the 
context of restenosis management, specifically targeting the therapeutic potential of resveratrol and 
quercetin. A novel drug delivery approach seeks to overcome challenges related to the limited 
bioavailability, rapid degradation, and clearance of polyphenolic compounds, which can hinder their 
effectiveness in mitigating restenosis. By encapsulating resveratrol and quercetin within biocompatible 
carriers, such as nanoparticles or microparticles, this new drug delivery system enables precise and 
controlled release of the active substances at the site of injury. The localized delivery mechanism holds 
the potential for sustained release over an extended period following stent implantation, thereby 
providing a prolonged therapeutic effect during the critical phase of vascular healing and restenosis 
prevention. The advantages of this approach lie in its ability to optimize the concentration of active 
compounds at the injury site, enhancing their therapeutic efficacy and reducing the risk of off-target 



Cluj Vet J 2023, vol 28, issue 2                                                                                                                         40 
 

effects or systemic toxicity. Furthermore, the controlled release kinetics ensure a continuous and targeted 
intervention, offering a more comprehensive and sustained response to restenosis. Despite the promising 
outlook, the successful translation of the new drug delivery system into clinical practice necessitates 
rigorous research and development. Key areas of focus include optimizing the carrier's biocompatibility, 
stability, and release profiles, as well as conducting thorough safety and efficacy assessments in 
preclinical and clinical settings. Such advancements in drug delivery technology hold substantial 
implications for the field of cardiovascular medicine. By leveraging the potential of this innovative 
approach, researchers and clinicians can improve restenosis management in both human and veterinary 
patients. However, challenges remain, such as ensuring regulatory compliance and addressing potential 
side effects, which require meticulous attention and further investigation. 

 
6. Conclusion 

In conclusion, the investigation of resveratrol and quercetin in the context of restenosis presents 
promising prospects for both human and veterinary medicine. Their antioxidant, anti-inflammatory, and 
anti-proliferative properties make them potential candidates for developing innovative therapeutic 
strategies. The exploration of a new drug delivery system offers a promising solution to enhance the 
therapeutic application of resveratrol and quercetin in restenosis management. The localized and 
sustained release of these polyphenolic compounds may revolutionize the approach to cardiovascular 
interventions, leading to more effective and targeted treatments for restenosis and ultimately improving 
patient outcomes in both veterinary and human medicine. As research progresses, a novel drug delivery 
system could become a transformative tool in the fight against restenosis, bridging the gap between 
scientific exploration and clinical application in the realm of cardiovascular health. 

 
Author Contributions: Conceptualization, IC.; writing—original draft preparation, I.C.; writing—review and editing, 
I.C.; visualization, I.C.; supervision, I.C. and F.G.B. All authors have read and agreed to the published version of the 
manuscript. 

Funding: This research received no external funding  

Institutional Review Board Statement: Not applicable 

Conflicts of Interest: The authors declare no conflict of interest. 

 

References 

1. Narayanaswamy, M., K.C. Wright, and K. Kandarpa, Animal models for atherosclerosis, restenosis, and endovascular graft 

research. Journal of vascular and interventional radiology: JVIR, 2000. 11(1): p. 5-17. DOI: 10.1016/s1051-0443(07)61271-8. 

2. Virmani, R. and A. Farb, Pathology of in-stent restenosis. Current opinion in lipidology, 1999. 10(6): p. 499-506. 

3. Koskinas, K.C., et al., Role of endothelial shear stress in-stent restenosis and thrombosis: pathophysiologic mechanisms and 

implications for clinical translation. Journal of the American College of Cardiology, 2012. 59(15): p. 1337-1349. 

DOI: 10.1016/j.jacc.2011.10.903. 

4. Schwartz, R.S., et al., Differential neointimal response to coronary artery injury in pigs and dogs. Implications for restenosis 

models. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994. 14(3): p. 395-400. DOI: 10.1161/01.atv.14.3.395. 

5. LU, A., et al., The effect of magnetic stent on coronary restenosis after percutaneous transluminal coronary angioplasty in 

dogs. Chinese Medical Journal, 2001. 114(08): p. 821-823. 

6. Tsang, H.-G., et al., Large animal models of cardiovascular disease. Cell biochemistry and function, 2016. 34(3): p. 113-132. 

https://doi.org/10.1016/s1051-0443(07)61271-8
https://doi.org/10.1016/j.jacc.2011.10.903
https://doi.org/10.1161/01.atv.14.3.395


Cluj Vet J 2023, vol 28, issue 2                                                                                                                         41 
 

7. Schwartz, R.S., et al., Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. 

Journal of the American College of Cardiology, 1992. 19(2): p. 267-274. DOI: 10.1016/0735-1097(92)90476-4. 

8. Sun, F., et al., Interventional cardiovascular techniques in small animal practice—diagnostic angiography and balloon 

valvuloplasty. Journal of the American Veterinary Medical Association, 2005. 227(3): p. 394-401. 

DOI: 10.2460/javma.2005.227.394. 

9. Ebert, M.L., et al., Animal models of neointimal hyperplasia and restenosis: species-specific differences and implications for 

translational research. Basic to Translational Science, 2021. 6(11): p. 900-917. DOI: 10.1016/j.jacbts.2021.06.006. 

10. Davis, C., et al., The role of inflammation in vascular injury and repair. Journal of Thrombosis and Haemostasis, 2003. 1(8): p. 

1699-1709. DOI: 10.1046/j.1538-7836.2003. 00292.x. 

11. Chistiakov, D.A., A.N. Orekhov, and Y.V. Bobryshev, Vascular smooth muscle cell in atherosclerosis. Acta physiologica, 2015. 

214(1): p. 33-50. DOI: 10.1111/apha.12466 

12. Mohindra, R., D.K. Agrawal, and F.G. Thankam, Altered vascular extracellular matrix in the pathogenesis of atherosclerosis. 

Journal of cardiovascular translational research, 2021: p. 1-14. DOI: 10.1007/s12265-020-10091-8 

13. Kibos, A., A. Campeanu, and I. Tintoiu, Pathophysiology of coronary artery in‐stent restenosis. Acute cardiac care, 2007. 9(2): 

p. 111-119. DOI: 10.1080/17482940701263285. 

14. Bertelli, A.A. and D.K. Das, Grapes, wines, resveratrol, and heart health. Journal of cardiovascular pharmacology, 2009. 54(6): 

p. 468-476. DOI: 10.1097/FJC.0b013e3181bfaff3. 

15. Di Santo, A., et al., Resveratrol and quercetin down-regulate tissue factor expression by human stimulated vascular cells. 

Journal of Thrombosis and Haemostasis, 2003. 1(5): p. 1089-1095. DOI: 10.1046/j.1538-7836.2003.00217.x.  

16. Nicholson, S.K., G.A. Tucker, and J.M. Brameld, Effects of dietary polyphenols on gene expression in human vascular 

endothelial cells. Proceedings of the Nutrition Society, 2008. 67(1): p. 42-47. DOI: 10.1017/S0029665108006009. 

17. Forte, A., et al., Novel potential targets for prevention of arterial restenosis: insights from the pre-clinical research. Clinical 

science, 2014. 127(11): p. 615-634. DOI: 10.1042/CS20140131. 

18. Chen, Y.-H., et al., Anti-inflammatory effects of different drugs/agents with antioxidant property on endothelial expression of 

adhesion molecules. Cardiovascular & Haematological Disorders-Drug Targets (Formerly Current Drug Targets-

Cardiovascular & Hematological Disorders), 2006. 6(4): p. 279-304. DOI: 10.2174/187152906779010737. 

19. Mirhadi, E., et al., Resveratrol: Mechanistic and therapeutic perspectives in pulmonary arterial hypertension. Pharmacological 

Research, 2021. 163: p. 105287.  DOI: 10.1016/j.phrs.2020.105287. 

20. Li, J., et al., Resveratrol: Potential Application in Sepsis. Front Pharmacol, 2022. 13: p. 821358. 

21. Kleinedler, J.J., et al., Synergistic effect of resveratrol and quercetin released from drug-eluting polymer coatings for 

endovascular devices. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 2011. 99(2): p. 266-275. 

DOI: 10.1002/jbm.b.31894. 

22. Zhu, Y., et al., Restenosis inhibition and re-differentiation of TGFβ/Smad3-activated smooth muscle cells by resveratrol. 

Scientific Reports, 2017. 7(1): p. 41916. DOI: 10.1038/srep41916. 

23. Upadhyay, S. and M. Dixit, Role of polyphenols and other phytochemicals on molecular signaling. Oxidative medicine and 

cellular longevity, 2015. DOI: 10.1155/2015/504253. 

24. Aghababaei, F. and M. Hadidi, Recent Advances in Potential Health Benefits of Quercetin. Pharmaceuticals, 2023. 16(7): p. 

1020. 

25. Frombaum, M., et al., Antioxidant effects of resveratrol and other stilbene derivatives on oxidative stress and NO 

bioavailability: Potential benefits to cardiovascular diseases. Biochimie, 2012. 94(2): p. 269-276. 

DOI: 10.1016/j.biochi.2011.11.001. 

26. Renaud, S.d. and M. de Lorgeril, Wine, alcohol, platelets, and the French paradox for coronary heart disease. The Lancet, 1992. 

339(8808): p. 1523-1526. DOI: 10.1016/0140-6736(92)91277-f. 

https://doi.org/10.1016/0735-1097(92)90476-4
https://doi.org/10.2460/javma.2005.227.394
https://doi.org/10.1016/j.jacbts.2021.06.006
https://doi.org/10.1046/j.1538-7836.2003.00292.x
https://doi.org/10.1111/apha.12466
https://doi.org/10.1007/s12265-020-10091-8
https://doi.org/10.1080/17482940701263285
https://doi.org/10.1097/fjc.0b013e3181bfaff3
https://doi.org/10.1046/j.1538-7836.2003.00217.x
https://doi.org/10.1017/s0029665108006009
https://doi.org/10.1042/cs20140131
https://doi.org/10.2174/187152906779010737
https://doi.org/10.1016/j.phrs.2020.105287
https://doi.org/10.1002/jbm.b.31894
https://doi.org/10.1038/srep41916
https://doi.org/10.1155/2015/504253
https://doi.org/10.1016/j.biochi.2011.11.001
https://doi.org/10.1016/0140-6736(92)91277-f


Cluj Vet J 2023, vol 28, issue 2                                                                                                                         42 
 

27. Burr, M.L., Explaining the French paradox. Journal of the Royal Society of Health, 1995. 115(4): p. 217-219. 

28. Renaud, S. and J.-C. Ruf, The French paradox: vegetables or wine. Circulation, 1994. 90(6): p. 3118-3119. 

29. Thanyasiri, P., et al., Endothelial dysfunction and restenosis following percutaneous coronary intervention. International 

journal of cardiology, 2007. 119(3): p. 362-367. DOI: 10.1016/j.ijcard.2006.08.015. 

30. Kearney, M., et al., Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation, 1997. 95(8): p. 

1998-2002. DOI: 10.1161/01.cir.95.8.1998. 

31. Jones, D.W., et al., Growing impact of restenosis on the surgical treatment of peripheral arterial disease. Journal of the 

American Heart Association, 2013. 2(6): p. e000345. DOI: 10.1161/JAHA.113.000345. 

32. Hajibandeh, S., et al., Treatment strategies for in-stent restenosis in peripheral arterial disease: a systematic review. Interactive 

cardiovascular and thoracic surgery, 2019. 28(2): p. 253-261. DOI: 10.1093/icvts/ivy233. 

33. Kantor, B., et al., The experimental animal models for assessing treatment of restenosis. Cardiovascular radiation medicine, 

1999. 1(1): p. 48-54. DOI: 10.1016/s1522-1865(98)00005-5. 

34. Iqbal, J., et al., Role of animal models in coronary stenting. Annals of biomedical engineering, 2016. 44: p. 453-465. 

35. Scott, N.A., Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the 

vascular response to injury. Advanced drug delivery reviews, 2006. 58(3): p. 358-376. DOI: 10.1016/j.addr.2006.01.015. 

36. Dardik, A., et al., Shear stress-stimulated endothelial cells induce smooth muscle cell chemotaxis via platelet-derived growth 

factor-BB and interleukin-1α. Journal of Vascular Surgery, 2005. 41(2): p. 321-331. DOI: 10.1016/j.jvs.2004.11.016. 

37. Ebert, M.L.A., et al., Animal Models of Neointimal Hyperplasia and Restenosis. JACC: Basic to Translational Science, 2021. 

6(11): p. 900-917. DOI: 10.1016/j.jacbts.2021.06.006. 

38. Frishman, W.H., P. Beravol, and C. Carosella, Alternative and Complementary Medicine for Preventing and Treating 

Cardiovascular Disease. Disease-a-Month, 2009. 55(3): p. 121-192. DOI: 10.1016/j.disamonth.2008.12.002. 

39. Li, M.-T., et al., The Protective Effect of Quercetin on Endothelial Cells Injured by Hypoxia and Reoxygenation. Frontiers in 

Pharmacology, 2021. 12. DOI: 10.3389/fphar.2021.732874. 

40. Moon, S.-K., et al., Quercetin exerts multiple inhibitory effects on vascular smooth muscle cells: role of ERK1/2, cell-cycle 

regulation, and matrix metalloproteinase-9. Biochemical and biophysical research communications, 2003. 301(4): p. 1069-1078. 

DOI: 10.1016/s0006-291x(03)00091-3. 

41. Fledderus, J., et al., The Endothelium as a Target for Anti-Atherogenic Therapy: A Focus on the Epigenetic Enzymes EZH2 

and SIRT1. Journal of Personalized Medicine, 2021. 11(2): p. 103. DOI: 10.3390/jpm11020103. 

42. Yoshizumi, M., et al., Quercetin glucuronide prevents VSMC hypertrophy by angiotensin II via the inhibition of JNK and AP-

1 signaling pathway. Biochemical and Biophysical Research Communications, 2002. 293(5): p. 1458-1465. DOI: 10.1016/S0006-

291X(02)00407-2. 

43. Heinz, S.A., et al., A 12-week supplementation with quercetin does not affect natural killer cell activity, granulocyte oxidative 

burst activity or granulocyte phagocytosis in female human subjects. Br J Nutr, 2010. 104(6): p. 849-57. 

DOI: 10.1017/S000711451000156X. 

44. Lin, X., et al., Quercetin improves vascular endothelial function through promotion of autophagy in hypertensive rats. Life 

Sciences, 2020. 258: p. 118106. DOI: 10.1016/j.lfs.2020.118106. 

45. Min, Y.D., et al., Quercetin inhibits expression of inflammatory cytokines through attenuation of NF-κB and p38 MAPK in 

HMC-1 human mast cell line. Inflammation Research, 2007. 56(5): p. 210-215. DOI: 10.1007/s00011-007-6172-9. 

46. Huang, B.-F., et al., The effect of quercetin on neointima formation in a rat artery balloon injury model. Pathology-Research 

and Practice, 2009. 205(8): p. 515-523. DOI: 10.1016/j.prp.2009.01.007. 

47. Thipparaboina, R., W. Khan, and A.J. Domb, Eluting combination drugs from stents. International Journal of Pharmaceutics, 

2013. 454(1): p. 4-10. DOI: 10.1016/j.ijpharm.2013.07.005. 

https://doi.org/10.1016/j.ijcard.2006.08.015
https://doi.org/10.1161/01.cir.95.8.1998
https://doi.org/10.1161/jaha.113.000345
https://doi.org/10.1093/icvts/ivy233
https://doi.org/10.1016/s1522-1865(98)00005-5
https://doi.org/10.1016/j.addr.2006.01.015
https://doi.org/10.1016/j.jvs.2004.11.016
https://doi.org/10.1016/j.jacbts.2021.06.006
https://doi.org/10.1016/j.disamonth.2008.12.002
https://doi.org/10.3389/fphar.2021.732874
https://doi.org/10.1016/s0006-291x(03)00091-3
https://doi.org/10.3390/jpm11020103
https://doi.org/10.1016/s0006-291x(02)00407-2
https://doi.org/10.1016/s0006-291x(02)00407-2
https://doi.org/10.1017/s000711451000156x
https://doi.org/10.1016/j.lfs.2020.118106
https://doi.org/10.1007/s00011-007-6172-9
https://doi.org/10.1016/j.prp.2009.01.007
https://doi.org/10.1016/j.ijpharm.2013.07.005


Cluj Vet J 2023, vol 28, issue 2                                                                                                                         43 
 

48. Dagher, O., et al., Therapeutic Potential of Quercetin to Alleviate Endothelial Dysfunction in Age-Related Cardiovascular 

Diseases. Frontiers in Cardiovascular Medicine, 2021. 8. DOI: 10.3389/fcvm.2021.658400. 

49. Cheng, K., et al., Protective effect of resveratrol against hepatic damage induced by heat stress in a rat model is associated 

with the regulation of oxidative stress and inflammation. Journal of thermal biology, 2019. 82: p. 70-

75.  DOI: 10.1016/j.jtherbio.2019.03.012. 

50. Zhou, X., et al., Resveratrol regulates mitochondrial reactive oxygen species homeostasis through Sirt3 signaling pathway in 

human vascular endothelial cells. Cell Death & Disease, 2014. 5(12): p. e1576-e1576. DOI: 10.1038/cddis.2014.530. 

51. Cheng, C.K., et al., Pharmacological basis and new insights of resveratrol action in the cardiovascular system. British Journal 

of Pharmacology, 2020. 177(6): p. 1258-1277. DOI: 10.1111/bph.14801. 

52. Clare, J., et al., The mechanisms of restenosis and relevance to next generation stent design. Biomolecules, 2022. 12(3): p. 430. 

DOI: 10.3390/biom12030430. 

53. Ara, C., et al., Protective effect of resveratrol against oxidative stress in cholestasis. Journal of Surgical Research, 2005. 127(2): 

p. 112-117. DOI: 10.1016/j.jss.2005.01.024. 

54. Xia, N., U. Förstermann, and H. Li, Resveratrol and endothelial nitric oxide. Molecules, 2014. 19(10): p. 16102-16121. 
DOI: 10.3390/molecules191016102. 

55. Klinge, C.M., et al., Resveratrol stimulates nitric oxide production by increasing estrogen receptor αa-Src-caveolin-1 

interaction and phosphorylation in human umbilical vein endothelial cells. The FASEB Journal, 2008. 22(7): p. 2185-2197. 

DOI: 10.1096/fj.07-103366. 

56. Diaz, M., et al., Acute resveratrol supplementation in coronary artery disease: Towards patient stratification. Scandinavian 

Cardiovascular Journal, 2020. 54(1): p. 14-19. DOI: 10.1080/14017431.2019.1657584. 

57. Elmadhun, N.Y., et al., The pig as a valuable model for testing the effect of resveratrol to prevent cardiovascular disease. 

Annals of the new York Academy of Sciences, 2013. 1290(1): p. 130-135. DOI: 10.1111/nyas.12216. 

58. 이미희, Application of bioactive compounds on small-caliber vascular graft for prevention of intimal hyperplasia. 2011, 

Graduate School, Yonsei University. 

59. Gu, J., et al., Effects of resveratrol on endothelial progenitor cells and their contributions to reendothelialization in intima-

injured rats. Journal of cardiovascular pharmacology, 2006. 47(5): p. 711-721. DOI: 10.1097/01.fjc.0000211764.52012.e3. 

60. Rodrigo, R., et al., Antioxidant Cardioprotection against Reperfusion Injury: Potential Therapeutic Roles of Resveratrol and 

Quercetin. Molecules, 2022. 27(8): p. 2564. DOI: 10.3390/molecules27082564. 

61.   Efovi, D.; Xiao, Q. Noncoding RNAs in Vascular Cell Biology and Restenosis. Biology 2023, 12, 24. 

https://doi.org/10.3390/biology12010024 

 

 

 

 

 

https://doi.org/10.3389/fcvm.2021.658400
https://doi.org/10.1016/j.jtherbio.2019.03.012
https://doi.org/10.1038/cddis.2014.530
https://doi.org/10.1111/bph.14801
https://doi.org/10.3390/biom12030430
https://doi.org/10.1016/j.jss.2005.01.024
https://doi.org/10.3390/molecules191016102
https://doi.org/10.1096/fj.07-103366
https://doi.org/10.1080/14017431.2019.1657584
https://doi.org/10.1111/nyas.12216
https://doi.org/10.1097/01.fjc.0000211764.52012.e3
https://doi.org/10.3390/molecules27082564
https://doi.org/10.3390/biology12010024

	1. Introduction
	References

